Small animal positron emission tomography imaging and in vivo studies of atherosclerosis

Clinical Physiology and Functional Imaging

Volumn 33, Issue 3, 2013, Pages 173-185

  Hag, Anne Mette Fisker ^a   Ripa, Rasmus Sejersten ^a   Pedersen, Sune Folke ^a   Bodholdt, Rasmus Poul ^a   Kjaer, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Atherosclerosis; in vivo; Mice; Molecular imaging; Non invasive; Positron emission tomography; Rabbits; Translational

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETATE C TYPE ARTERIAL NATRIURETIC FACTOR CU 64; ATORVASTATIN; CD68 ANTIGEN; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; GALACTO ARGINYLGLYCYLASPARTIC ACID F 18; PIOGLITAZONE; PROBUCOL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ATHEROSCLEROSIS; COMPUTER ASSISTED TOMOGRAPHY; DESTRUCTION; IN VIVO STUDY; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY SIZE; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RABBITS; RADIOPHARMACEUTICALS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84875619414     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/cpf.12017     Document Type: Review

References (82)

1. Alavi A, Reivich M. Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med (2002); 32: 2-5.
2. -/- mice. Arterioscler Thromb Vasc Biol (2003); 23: 1077-1082.
3. Antonov AS, Kolodgie FD, Munn DH, Gerrity RG. Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. Am J Pathol (2004); 165: 247-258.
4. Bentzon JF, Falk E. Atherosclerotic lesions in mouse and man: is it the same disease. Curr Opin Lipidol (2010); 21: 434-440.
5. Bloomfield PM, Rajeswaran S, Spinks TJ, Hume SP, Myers R, Ashworth S, Clifford KM, Jones WF, Byars LG, Young J. The design and physical characteristics of a small animal positron emission tomograph. Phys Med Biol (1995); 40: 1105-1126.
6. Breyholz H-J, Wagner S, Faust A, Riemann B, Höltke C, Hermann S, Schober O, Schäfers M, Kopka K. Radiofluorinated pyrimidine-2, 4, 6-triones as molecular probes for noninvasive MMP-targeted imaging. ChemMedChem (2010); 5: 777-789.
7. Brousseau ME, Hoeg JM. Transgenic rabbits as models for atherosclerosis research. J Lipid Res (1999); 40: 365-375.
8. Calcagno C, Cornily J-C, Hyafil F, Rudd JHF, Briley-Saebo KC, Mani V, Goldschlager G, Machac J, Fuster V, Fayad ZA. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol (2008); 28: 1311-1317.
9. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem (2002); 50: 799-809.
10. Chatziioannou AF. Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proc Am Thorac Soc (2005); 2: 533-536, 510-11.
11. Cherry SR. The 2006 Henry N. Wagner Lecture: of mice and men (and positrons)-advances in PET imaging technology. J Nucl Med (2006); 47: 1735-1745.
12. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol (2007); 50: 2357-2368.
13. Davies JR, Izquierdo-Garcia D, Rudd JHF, Figg N, Richards HK, Bird JLE, Aigbirhio FI, Davenport AP, Weissberg PL, Fryer TD, Warburton EA. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc Imaging (2010); 26: 41-48.
14. Dupont P, Warwick J. Kinetic modelling in small animal imaging with PET. Methods (2009); 48: 98-103.
15. Elmaleh DR, Fischman AJ, Tawakol A, Zhu A, Shoup TM, Hoffmann U, Brownell A-L, Zamecnik PC. Detection of inflamed atherosclerotic lesions with diadenosine-5′, 5′"-"P1, P4-tetraphosphate (Ap4A) and positron-emission tomography. Proc Natl Acad Sci USA (2006); 103: 15992-15996.
16. Falk E, Sillesen H, Muntendam P, Fuster V. The high-risk plaque initiative: primary prevention of atherothrombotic events in the asymptomatic population. Curr Atheroscler Rep (2011); 13: 359-366.
17. Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis (1997); 135: 1-7.
18. Fisker Hag AM, Pedersen SF, Kjaer A. Gene expression of LOX-1, VCAM-1, and ICAM-1 in pre-atherosclerotic mice. Biochem Biophys Res Commun (2008); 377: 689-693.
19. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol (2007); 27: 2292-2301.
20. Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol (2012); 32: 1104-1115.
21. Graebe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg (2009); 37: 714-721.
22. Hag AMF, Pedersen SF, Christoffersen C, Binderup T, Jensen MM, Jørgensen JT, Skovgaard D, Ripa RS, Kjaer A. 18F-FDG PET Imaging of Murine Atherosclerosis: association with Gene Expression of Key Molecular Markers. PLoS ONE (2012); 7: e50908.
23. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging (2010); 37(Suppl 1): S86-S103.
24. Hugenberg V, Breyholz H-J, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S. A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio) synthesis and in vitro and first in vivo evaluation. J Med Chem (2012); 55: 4714-4727.
25. Hyafil F, Cornily J-C, Rudd JHF, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med (2009); 50: 959-965.
26. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest (1993); 92: 883-893.
27. Jarrett BR, Correa C, Ma KL, Louie AY. In vivo mapping of vascular inflammation using multimodal imaging. PLoS ONE (2010); 5: e13254.
28. Jawień J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol (2004); 55: 503-517.
29. Joshi F, Rosenbaum D, Bordes S, Rudd JHF. Vascular imaging with positron emission tomography. J Intern Med (2011); 270: 99-109.
30. de Kemp RA, Epstein FH, Catana C, Tsui BMW, Ritman EL. Small-animal molecular imaging methods. J Nucl Med (2010); 51(Suppl 1): 18S-32S.
31. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, Leppänen P, Ylä-Herttuala S, Hölzlwimmer G, Walch A, Esposito I, Wester H-J, Knuuti J, Schwaiger M. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging (2009); 2: 331-338.
32. Lee SJ, On YK, Lee EJ, Choi JY, Kim B-T, Lee K-H. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med (2008); 49: 1277-1282.
33. Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med (2010); 51(Suppl 1): 33S-37S.
34. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost (2011); 106: 827-838.
35. Liu Y, Abendschein D, Woodard GE, Rossin R, McCommis K, Zheng J, Welch MJ, Woodard PK. Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET. J Nucl Med (2010); 51: 85-91.
36. Lobatto ME, Fayad ZA, Silvera S, Vucic E, Calcagno C, Mani V, Dickson SD, Nicolay K, Banciu M, Schiffelers RM, Metselaar JM, van Bloois L, Wu H-S, Fallon JT, Rudd JH, Fuster V, Fisher EA, Storm G, Mulder WJM. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010); 7: 2020-2029.
37. Mankoff DA. A definition of molecular imaging. J Nucl Med (2007); 48: 18N, 21N.
38. Matter CM, Wyss MT, Meier P, Späth N, von Lukowicz T, Lohmann C, Weber B, de Molina AR, Lacal JC, Ametamey SM, von Schulthess GK, Luscher TF, Kaufmann PA, Buck A. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscl Thromb Vasc Biol (2006); 26: 584-589.
39. Moreno PR, Purushothaman KR, Zias E, Sanz J, Fuster V. Neovascularization in human atherosclerosis. Curr Mol Med (2006); 6: 457-477.
40. Muntendam P, McCall C, Sanz J, Falk E, Fuster V, High-Risk Plaque Initiative. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am Heart J (2010); 160: 49-57.
41. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2008); 117: 379-387.
42. Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo J-L, Aikawa E, Kelly K, Libby P, Weissleder R. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging (2009); 2: 1213-1222.
43. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, Kudomi N, Shiomi M, Magata Y, Iida H, Saji H. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med (2004); 45: 1245-1250.
44. Ogawa M, Magata Y, Kato T, Hatano K, Ishino S, Mukai T, Shiomi M, Ito K, Saji H. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med (2006); 47: 1845-1850.
45. Owen DRJ, Lindsay AC, Choudhury RP, Fayad ZA. Imaging of atherosclerosis. Annu Rev Med (2011); 62: 25-40.
46. Paulmier B, Duet M, Khayat R, Pierquet-Ghazzar N, Laissy J-P, Maunoury C, Hugonnet F, Sauvaget E, Trinquart L, Faraggi M. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol (2008); 15: 209-217.
47. Pedersen SF, Graebe M, Fisker Hag AM, Højgaard L, Sillesen H, Kjaer A. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun (2010); 31: 423-429.
48. Pedersen SF, Graebe M, Hag AMF, Hoejgaard L, Sillesen H, Kjaer A. Microvessel density but not neoangiogenesis is associated with (18)F-FDG uptake in human atherosclerotic carotid plaques. Mol Imaging Biol (2012); 14: 384-392.
49. Phelps ME PET: Molecular Imaging and its Biological Applications, 1st edn (2004). Springer Science+Business Media, Inc., New York.
50. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med (1975); 16: 210-224.
51. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell (1992); 71: 343-353.
52. Riemann B, Schäfers KP, Schober O, Schäfers M. Small animal PET in preclinical studies: opportunities and challenges. Q J Nucl Med Mol Imaging (2008); 52: 215-221.
53. Riou LM, Broisat A, Dimastromatteo J, Pons G, Fagret D, Ghezzi C. Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview. Curr Med Chem (2009); 16: 1499-1511.
54. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation (2012); 125: e2-e220.
55. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology (2004); 231: 305-332.
56. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, Nikolaou K, Reiser MF, Bartenstein P, Hacker M. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med (2009); 50: 1611-1620.
57. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med (1999); 340: 115-126.
58. Rudd JHF, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnström P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation (2002); 105: 2708-2711.
59. Rudd JHF, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, Farkouh ME, Fayad ZA. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009); 2: 107-115.
60. Saraste A, Laitinen I, Weidl E, Wildgruber M, Weber AW, Nekolla SG, Hölzlwimmer G, Esposito I, Walch A, Leppänen P, Lisinen I, Luppa PB, Ylä-Herttuala S, Wester H-J, Knuuti J, Schwaiger M. Diet intervention reduces uptake of α(v)β (3) integrin-targeted PET tracer (18)F-galacto-RGD in mouse atherosclerotic plaques. J Nucl Cardiol (2012); 19: 775-784.
61. Sharif F, Lohan DG, Wijns W. Non-invasive detection of vulnerable coronary plaque. World J Cardiol (2011); 3: 219-229.
62. Sheikine Y, Akram K. FDG-PET imaging of atherosclerosis: do we know what we see. Atherosclerosis (2010); 211: 371-380.
63. -/-ApoB100/100 mice. EJNMMI Res (2011a); 1: 14.
64. Silvola JMU, Saraste A, Laitinen I, Savisto N, Laine VJO, Heinonen SE, Ylä-Herttuala S, Saukko P, Nuutila P, Roivainen A, Knuuti J. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging (2011b); 4: 1294-1301.
65. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med (2007); 48: 932-945.
66. Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol (2005); 12: 294-301.
67. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol (2006); 48: 1818-1824.
68. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology (1975); 114: 89-98.
69. Vucic E, Dickson SD, Calcagno C, Rudd JHF, Moshier E, Hayashi K, Mounessa JS, Roytman M, Moon MJ, Lin J, Tsimikas S, Fisher EA, Nicolay K, Fuster V, Fayad ZA. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging (2011); 4: 1100-1109.
70. Vucic E, Calcagno C, Dickson SD, Rudd JHF, Hayashi K, Bucerius J, Moshier E, Mounessa JS, Roytman M, Moon MJ, Lin J, Ramachandran S, Tanimoto T, Brown K, Kotsuma M, Tsimikas S, Fisher EA, Nicolay K, Fuster V, Fayad ZA. Regression of Inflammation in Atherosclerosis by the LXR Agonist R211945: a Noninvasive Assessment and Comparison With Atorvastatin. JACC Cardiovasc Imaging (2012); 5: 819-828.
71. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis (1980); 36: 261-268.
72. WHO GHO World Health Statistics 2012 (2012), pp. 1-130. WHO Press, Geneva, Switzerland.
73. Worthley SG, Zhang ZY, Machac J, Helft G, Tang C, Liew GYH, Zaman AG, Worthley MI, Fayad ZA, Buchsbaum MS, Fuster V, Badimon JJ. In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiovasc Imaging (2009); 25: 251-257.
74. Wyss MT, Weber B, Honer M, Späth N, Ametamey SM, Westera G, Bode B, Kaim AH, Buck A. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging (2004); 31: 312-316.
75. Xiangdong L, Yuanwu L, Hua Z, Liming R, Qiuyan L, Ning L. Animal models for the atherosclerosis research: a review. Protein Cell (2011); 2: 189-201.
76. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J. Animal models of cardiovascular diseases. J Biomed Biotechnol (2011); 2011: 497841.
77. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (1992); 258: 468-471.
78. Zhang Z, Machac J, Helft G, Worthley SG, Tang C, Zaman AG, Rodriguez OJ, Buchsbaum MS, Fuster V, Badimon JJ. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med (2006); 6: 3.
79. -/- mice. Eur J Nucl Med Mol Imaging (2007); 34: 1747-1755.
80. 99mTc-annexin A5 uptake in apolipoprotein E-deficient and wild-type C57BL/6J mice. J Nucl Med (2008); 49: 1707-1714.
81. Zhao Q-M, Feng T-T, Zhao X, Xu Z-M, Liu Y, Li D-P, Li L-Q, Su G, Zhang X-X. Imaging of atherosclerotic aorta of rabbit model by detection of plaque inflammation with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Chin Med J (2011a); 124: 911-917.
82. Zhao Y, Zhao S, Kuge Y, Strauss WH, Blankenberg FG, Tamaki N. Localization of deoxyglucose and annexin A5 in experimental atheroma correlates with macrophage infiltration but not lipid deposition in the lesion. Mol Imaging Biol (2011b); 13: 712-720.